GRIFOLS reported EUR5.46B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Alcon AG USD 22.13B 99M Mar/2026
Almirall EUR 1.49B 24.03M Dec/2025
Amadeus IT EUR 4.8B 49.7M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
argenx SE USD 7.32B 1.23B Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Cie Automotive EUR 1.45B 46.93M Dec/2025
Demant DKK 9.84B 446M Dec/2025
Ence Energia y Celulosa EUR 496.44M 106.36M Dec/2025
Essilor EUR 38.89B 1.07B Dec/2025
Ferrovial EUR 7.66B 11M Dec/2025
Fresenius EUR 19.77B 1.14B Dec/2025
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Genmab DKK 5.85B 96M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
GRIFOLS EUR 5.46B 171M Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Inditex 18.8B 1.84B Sep/2025
Lakefront Biotherapeutics EUR 3.25B 17.5M Mar/2026
Merck EUR 29.74B 1.15B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Philips EUR 11.39B 403M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Smith & Nephew USD 5.54B 331M Dec/2025
UCB EUR 10.87B 1.18B Dec/2025
Viscofan EUR 932.04M 4.41M Mar/2026